Aria Pharmaceuticals

What Aria Pharmaceuticals does

Aria Pharmaceuticals is a Palo Alto-based, privately held biopharmaceutical company founded in 2014 that positions itself as an AI-driven drug discovery organization. The company operates with a small team (11-50 employees) and is led by founder and CEO Andrew A. Radin, with operational leadership spanning discovery (Aaron Daugherty, VP Discovery), R&D (Mark Eller, SVP R&D), business development (Allen Poirson, SVP Biopharmaceutical BD), and human resources (Melissa Horton, Head of HR). The website (ariapharmaceuticals.com) is currently inaccessible, limiting direct verification of pipeline details, platform architecture, or program status.

The company has raised approximately $14.3M across four disclosed funding rounds between 2015 and 2021, anchored by top-tier venture capital. Andreessen Horowitz led the 2015 seed ($3.4M) alongside CLI Ventures and StartX (Stanford-StartX Fund), then participated in the 2018 Series A ($10M) led by SBVA with OS Fund. A 2021-07-09 round added undisclosed capital from Future Planet Capital, Network.VC, and Silicon Valley Syndicate Club. No product launches, partnerships, acquisitions, or licensing deals are documented in the available source material.

Given the small headcount, total disclosed funding in the low-teens of millions, absence of customer logos or partnership disclosures, and R&D-stage leadership composition, Aria's business model is consistent with a preclinical AI-drug-discovery platform that would monetize through pharma collaborations, out-licensing deals, or milestone-based partnerships rather than product sales. Specific pricing, revenue mechanics, customer segments, and pipeline indications cannot be verified from the supplied data.

Name

Aria Pharmaceuticals

Website

https://ariapharmaceuticals.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Aria Pharmaceuticals is a Palo Alto-based, privately held AI-driven biopharmaceutical company founded in 2014, using machine learning for drug discovery and supported by ~$14.3M in disclosed venture funding across 2015-2021.

Ownership category

akta.pro rank

Product category

Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), In Silico / Computational Toxicology & PK/PD Modeling (HLAGAFAM)

Keywords

• AI-driven drug discovery
• Biopharmaceutical research
• Computational drug development
• Pharmaceutical R&D
• Machine learning therapeutics

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Core offering

Aria Pharmaceuticals is an AI-driven biopharmaceutical company focused on discovering and developing new therapeutic drug candidates using machine learning and computational approaches. The company applies artificial intelligence to accelerate the identification and optimization of novel compounds for pharmaceutical applications. Its operations center on AI-enabled preclinical drug discovery research rather than the manufacture or sale of marketed pharmaceutical products.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-driven drug discovery programs

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights3 records

Direct peers

• Insitro: Machine-learning-driven drug discovery company combining induced pluripotent stem cell biology with AI models. Insitro directly parallels Aria's positioning as an AI-native biopharma pursuing both partnered and internal programs.
• BenevolentAI: AI-driven drug discovery company using knowledge graphs and ML to identify novel targets and therapeutics. BenevolentAI is a directly comparable AI-biopharma with both partnered programs and an internal pipeline, similar in commercial model to Aria.
• Recursion Pharmaceuticals: AI-driven biopharma combining high-throughput biology with ML to discover therapeutics. Like Aria, Recursion is a small-molecule-focused platform player using computational methods to identify novel targets and drug candidates for pharma partners and internal pipelines.
• Atomwise: AI-driven small-molecule drug discovery company using structure-based deep learning to identify novel compounds. Atomwise operates a partnership-heavy model closely aligned with how an AI-platform biopharma like Aria monetizes its technology.
• Exscientia: AI-driven precision medicine company that uses its platform to design and develop small-molecule therapeutics. Direct competitor to Aria in AI-first small-molecule drug design and pharma partnership model.

Broad incumbents

• Schrödinger: Computational chemistry and materials science platform with a therapeutics arm. Schrödinger is a broader, more established incumbent that uses physics-based modeling and ML for drug discovery — comparable to Aria's computational approach but with much greater scale and a public-market profile.
• Isomorphic Labs: Alphabet-backed AI drug discovery company applying DeepMind's protein-structure and generative models to pharma. Represents the well-capitalized end of Aria's competitive set and a potential partner or acquirer of smaller AI-platform biopharmas.

Emerging players

• Iambic Therapeutics: AI-driven drug discovery company that combines physics-based modeling with ML to design differentiated small molecules. Iambic is a comparable emerging platform player competing in the same AI-first therapeutic discovery category as Aria.
• Cradle Bio: AI platform for protein and biologics engineering. Cradle extends AI-driven discovery into biologics design — adjacent to Aria's discovery ambitions and a useful comparable for how lean AI-platform teams monetize through partnerships.
• XtalPi: AI- and quantum-physics-driven drug discovery and crystal-form prediction company. XtalPi combines computational and experimental platforms to identify small molecules — overlapping with Aria's AI-driven biopharma approach.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights5 records

Customer concentration

• Xx.com/ariapharma
• Facebookfacebook.com/ariapharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aria Pharmaceuticals